1-5 of 5
Wendy Y. Cheng, MPH, MPhil
Close
Sort by
Journal Articles

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Elias J. Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, Nora McCormick, MSc, Wendy Y. Cheng, MPH, MPhil, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD MBA, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 5189.
https://doi.org/10.1182/blood.V128.22.5189.5189
Published: 2016
Journal Articles

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Elliott P. Vichinsky, MD, Janet Kwiatkowski, MD, Patricia J. Giardina, MD, Carole Paley, MD, Francis Vekeman, MA, Wendy Y. Cheng, MPH, MPhil, Joseph Damron, BA, Nora McCormick, MSc, Medha Sasane, PhDBPharm,MS, Ying Qiu, PhD, Mei Sheng Duh, MPH, ScD, Alexis A. Thompson, MD
Journal: Blood
Blood (2015) 126 (23): 3279.
https://doi.org/10.1182/blood.V126.23.3279.3279
Published: 2015
Journal Articles

Adherence to Iron Chelation Therapy and Associated Healthcare Resource Utilization and Costs in Medicaid Patients with Sickle Cell Disease

Francis Vekeman, MA, Medha Sasane, BPharm, PhD, Wendy Y Cheng, MPH, MPhil, Agnihotram V Ramanakumar, PhD, Jonathan Fortier, MA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Patricia Adams-Graves, MD
Journal: Blood
Blood (2014) 124 (21): 2177.
https://doi.org/10.1182/blood.V124.21.2177.2177
Published: 2014
Journal Articles

Medical Complications In Patients With Myelofibrosis By Frequency Of Blood Transfusion and Iron Chelation Therapy

Francis Vekeman, MA, Wendy Y Cheng, MPH, MPhil, Medha Sasane, BPharm, PhD, Lynn Huynh, MPH, MBA, DrPH, Michael Kaminsky, BA, Mei S. Duh, ScD, MPH, Carole Paley, MD, Ruben A. Mesa, MD
Journal: Blood
Blood (2013) 122 (21): 2964.
https://doi.org/10.1182/blood.V122.21.2964.2964
Published: 2013
Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Shaji K Kumar, MD, Ann E Engebretson, Francis K Buadi, MD, Martha Q Lacy, MD, Angela Dispenzieri, MD, Mei Sheng Duh, MPH, Sc.D, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, B.Sc, Wendy Y Cheng, MPH, MPhil, Katherine Dea, MA, Mark Yap, BSN, RN, Shanmugapriya Saravanan, MS, Iwen Pan, Ph.D, Debra Rembert, RN, MSN, NP, Rahul Dhanda, PhD, Liviu Niculescu, MD, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Maureen Quick, RN, MS, OCN, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2013) 122 (21): 3178.
https://doi.org/10.1182/blood.V122.21.3178.3178
Published: 2013